REMARKS

Claims 24-35 are now pending, with claim 24 being the sole independent claim.

Claims 1-23 have been canceled without prejudice to or disclaimer of the subject matter recited therein.

Claims 24-35 have been added. Support for the sequence identities and the pairwise alignment default parameters for the Clustal method of alignment recited in claims 24-26 is found at least in the paragraph beginning on line 1 of page 6 of the specification. Support for the use of the term "recombinant" in claims 30, 32, and 34-35 is found at least in the paragraph beginning on line 13 of page 10 of the specification. Support for claims 33-35 are found at least in Examples 6-7, pages 20-24 of the specification. No new matter has been added.

The specification has been amended at two locations to remove reference to the following URL: www.ncbi.nlm.nih.gov/BLAST/.

The specification has been amended to remove reference to SEQ ID NO:19 in Example 3, the paragraph at page 18, lines 5-7. As described in Example 3, SEQ ID NO:19 should correspond to the amino acid sequence of GI No. 2997684, which is referenced in Table 4. In the creation of SEQ ID NO:19 for the sequence listing, the 107 amino acid sequence of GI No. 2997684 was saved in a computer as a nucleotide sequence file, instead of as an amino acid sequence file. This error resulted in SEQ ID NO:19 containing only 83 amino acids, instead of 107 amino acids. Since Table 4 makes reference to GI No. 2997684, and the data presented in Table 4 correctly indicate the percent sequence identities of SEQ ID NOs:2, 4, 6, 8, 10 and 12, as compared to the 107 amino acid sequence of GI No. 2997684, the reference to SEQ ID NO:19 is not required to describe or practice the current invention, and has been deleted to avoid confusion. No new matter has been added.

The specification has been amended to correct a clerical error in Table 6, on page 19, of Example 4. The correct GI No. for Table 6 should cite GI No. 2997686, instead of GI No. 2997684. GI No. 2997686 is cited on line 5, page 19, and in Table 5, page 19, both in Example 4. The paragraph beginning on line 13, page 19, of Example 4 makes reference to SEQ ID NO:20 as being used to generate the data of Table 6. The amino acid sequence in SEQ ID NO:20 corresponds to the amino acid sequence of GI No. 2997686. No new matter has been added.

## <u>RESPONSE TO RESTRICTION REQUIREMENT</u>

In response to the Restriction Requirement in the Office Action mailed September 28, 2004, Applicants hereby elect, without traverse, Group I , claims 1-5, 7-11, 13-17, 22 and 23, drawn to a polynucleotide, classified in class 800, subclass 295, and further elect Invention (B), SEQ ID No:3 or a sequence encoding SEQ ID No:4. Applicants believe new Claims 24-35 are directed to Group I, Invention (B).

The 101 amino acid sequence of SEQ ID NO:4 is encoded by nucleotides 46-348 of SEQ ID NO:3. An in-frame stop codon is encoded by nucleotides 349-351 of SEQ ID NO:3.

Please charge any fees or credit any overpayment of fees which are required in connection herewith to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Allowance of the above-referenced application is respectfully requested.

Respectfully submitted,

EMIL M. OROZCO, JR.
AGENT FOR APPLICANTS
REGISTRATION NO. 50,823
TELEPHONE: 302-695-3121
FACSIMILE: 302-892-1026

Dated: _October 19, 2004_